Evidence map›Paper›PMID 42903374›Full record

ReviewFrontiers in immunology2026

Review on the significance and clinical application of anti-p53 autoantibody detection.

Fan Bu, Zhe-Nan Ling, Pei Li, Bin Zhou, Wang-Yu Zhu, Jiu-Li Wang, Xiang Liu, Tian-Yu Zhu, Yi-An Du, Qiu-Lei Lang and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Fan BuZhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Zhe-Nan LingDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Pei LiDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, High-Tech Zone, Zhengzhou, Henan, China.
Bin ZhouDepartment of General Surgery, Taixing People's Hospital, Yangzhou University, Taixing, Jiangsu, China.
Wang-Yu ZhuCell and Molecular Biology Laboratory, Zhoushan Hospital, Zhoushan, Zhejiang, China.
Jiu-Li WangDepartment of Medical Oncology, Bozhou Hospital of Traditional Chinese Medicine, Bozhou, Anhui, China.
Xiang LiuDepartment of Laboratory Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
Tian-Yu ZhuDepartment of Surgery, Jinhua People's Hospital, Jindong District, Jinhua, Zhejiang, China.
Yi-An DuDepartment of Surgery, Zhejiang Hospital, Hangzhou, Zhejiang, China.
Qiu-Lei LangDepartment of Molecular Diagnostics, Hangzhou Lianchuan Biotechnology Co., Hangzhou, Zhejiang, China.
Liu-Hui ZhouZhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Zi-Yan JinZhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Wen-Jing WangZhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Yi-Xuan LiZhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Yu-Zhen ZhangZhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Xia-Ying DuZhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Zhi-Qiang LingZhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a critical tumor suppressor gene, mutations in p53 often contribute to the initiation and progression of cancer. Anti-p53 autoantibody (p53-AAb), produced by the immune system in response to mutated p53 protein, can be detected in the blood during early stages of tumor development. As a non-invasive biomarker, p53-AAb demonstrates potential for early screening, auxiliary diagnosis, prognosis evaluation, and treatment monitoring across various cancer types. Based on current literature and evidence-based medical data, this Review Article provides an overview of the scientific rationale, technical aspects, and clinical applications of p53-AAb testing. It summarizes practical considerations to guide scientific research and clinical practice, with the aim of promoting standardized utilization of this biomarker.

Indexed as

AutoantibodiesBiomarkers, TumorNeoplasmsTumor Suppressor Protein p53AnimalsHumansMutationPrognosisAutoantibodiesBiomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53cancer diagnosisimmunoassayP53 autoantibodyprecision medicinetumor marker

Identifiers

PMID42903374
PMCPMC13681304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.